The FDA-cleared Vantera Clinical Analyzer combines proprietary signal-processing algorithms and NMR spectroscopic detection to identify and quantify concentrations of lipoproteins and small-molecule metabolites.

LipoScience chief executive officer Richard Brajer said the company is pioneering a new field of personalized diagnostics based on NMR technology.

"Broadening access to our proprietary diagnostic tests is central to our vision of becoming a clinical standard of care," Brajer added.

"We value Agilent’s NMR expertise and look forward to partnering with them in our efforts to decentralize our NMR clinical analyzer to leading clinical laboratories and academic centers of excellence."